Interferon-γ and granulocyte-macrophage colony stimulating factor therapy in three patients with pulmonary aspergillosis

A. Bandera, D. Trabattoni, G. Ferrario, M. Cesari, F. Franzetti, M. Clerici, A. Gori

Research output: Contribution to journalArticlepeer-review

Abstract

An immune response mediated by type 2 cytokines is thought to contribute to the development and unfavorable outcome of aspergillosis. Adjuvant therapy with interferon-γ (IFN-γ) and granulocyte-macrophage colony stimulating factor (GM-CSF) was added to antifungal treatment in three nonneutropenic patients (one HIV-positive and two HIV-negative patients) with culture proven aspergillosis refractory to classical antifungal therapy. Clinical improvement was observed concomitantly with an increase in peripheral blood leukocyte proliferation and type 1 cytokines production. Our findings suggest an association between the improvement in type 1 cytokine production observed during IFN-γ and GM-CSF administration and a better control of Aspergillus infection in patients with progressive disease despite adequate antifungal therapy.

Original languageEnglish
Pages (from-to)368-373
Number of pages6
JournalInfection
Volume36
Issue number4
DOIs
Publication statusPublished - Aug 2008

ASJC Scopus subject areas

  • Microbiology (medical)
  • Immunology

Fingerprint Dive into the research topics of 'Interferon-γ and granulocyte-macrophage colony stimulating factor therapy in three patients with pulmonary aspergillosis'. Together they form a unique fingerprint.

Cite this